Data I/O (DAIO) Competitors

Akoya Biosciences (NASDAQ:AKYA) and Data I/O (NASDAQ:DAIO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.

Do analysts rate AKYA or DAIO?

Akoya Biosciences presently has a consensus target price of $3.62, indicating a potential upside of 152.91%. Data I/O has a consensus target price of $4.00, indicating a potential upside of 59.36%. Given Akoya Biosciences' higher possible upside, equities research analysts clearly believe Akoya Biosciences is more favorable than Data I/O.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akoya Biosciences	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Data I/O	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is AKYA or DAIO more profitable?

Data I/O has a net margin of -7.53% compared to Akoya Biosciences' net margin of -66.77%. Data I/O's return on equity of -9.05% beat Akoya Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akoya Biosciences	-66.77%	-162.99%	-32.76%
Data I/O	-7.53%	-9.05%	-6.89%

Does the MarketBeat Community believe in AKYA or DAIO?

Data I/O received 140 more outperform votes than Akoya Biosciences when rated by MarketBeat users. Likewise, 66.79% of users gave Data I/O an outperform vote while only 58.33% of users gave Akoya Biosciences an outperform vote.

Company	Underperform	Outperform
Akoya Biosciences	Outperform Votes 35 58.33%	Underperform Votes 25 41.67%
Data I/O	Outperform Votes 175 66.79%	Underperform Votes 87 33.21%

Do institutionals and insiders believe in AKYA or DAIO?

79.4% of Akoya Biosciences shares are held by institutional investors. Comparatively, 37.0% of Data I/O shares are held by institutional investors. 7.3% of Akoya Biosciences shares are held by insiders. Comparatively, 7.3% of Data I/O shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has better earnings and valuation, AKYA or DAIO?

Data I/O has lower revenue, but higher earnings than Akoya Biosciences. Data I/O is trading at a lower price-to-earnings ratio than Akoya Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akoya Biosciences	$81.67M	0.87	-$63.32M	-$1.13	-1.27
Data I/O	$21.77M	1.06	$490K	-$0.34	-7.38

Does the media prefer AKYA or DAIO?

In the previous week, Akoya Biosciences had 8 more articles in the media than Data I/O. MarketBeat recorded 11 mentions for Akoya Biosciences and 3 mentions for Data I/O. Data I/O's average media sentiment score of 0.96 beat Akoya Biosciences' score of 0.27 indicating that Data I/O is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akoya Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Data I/O	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, AKYA or DAIO?

Akoya Biosciences has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Data I/O has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.

Summary

Data I/O beats Akoya Biosciences on 11 of the 17 factors compared between the two stocks.